Computed tomographic scanning of the lung in patients with allergic bronchopulmonary aspergillosis and in asthmatic patients with a positive skin test to *Aspergillus fumigatus*

R M Angus, M-L Davies, M D Cowan, C McSharry, N C Thomson

**Abstract**

**Background** – Allergic bronchopulmonary aspergillosis is a disease of asthmatic patients which may follow a protracted course and result in chronic lung damage such as central bronchiectasis. In asthma uncomplicated by allergic bronchopulmonary aspergillosis, in particular in asthmatic patients with immediate hypersensitivity type skin reactions to *Aspergillus fumigatus*, the incidence of bronchiectasis is uncertain.

**Methods** – Computed tomographic (CT) scans were performed in 17 asthmatic patients of mean (SE) age 60.1 (2.5) years, FEV$_1$ 49.4 (5.8)% predicted with allergic bronchopulmonary aspergillosis (all with current or previous positive precipitins to A fumigatus) and in 11 asthmatic patients of mean (SE) age 49.5 (5.8) years, FEV$_1$ 75.5 (6.5) % predicted, skin test positive for *A fumigatus*, but without the clinical or serological features of allergic bronchopulmonary aspergillosis (non-allergic bronchopulmonary aspergillosis group).

**Results** – Bronchial dilatation was more common in the group with allergic bronchopulmonary aspergillosis, affecting 14 patients compared with two in the non-allergic bronchopulmonary aspergillosis group. Evidence of bronchiectasis was found in 43 of a possible 102 lobes of patients with allergic bronchopulmonary aspergillosis, compared with three of a possible 66 in the non-allergic bronchopulmonary aspergillosis group. Bronchial wall thickening was common to both, affecting 16 and nine patients respectively. Pleural thickening on CT scanning was common in the group with allergic bronchopulmonary aspergillosis, being noted in 14 patients compared with only three in the non-allergic bronchopulmonary aspergillosis group.

**Conclusions** – Bronchiectasis is common in allergic bronchopulmonary aspergillosis but occurs only occasionally in asthmatic patients with a positive skin test to *A fumigatus* but without other features of the disease.

(Thorax 1994;49:586-589)

Allergic bronchopulmonary aspergillosis is a disease of asthmatic patients characterised by a potent humoral immune response to *Aspergillus fumigatus*. It may follow a protracted course and may progress to result in chronic lung damage such as central bronchiectasis or pulmonary fibrosis. $^{1,2}$

Until recently it has been generally accepted that central bronchiectasis was virtually pathognomonic for the diagnosis of allergic bronchopulmonary aspergillosis and not a feature of uncomplicated asthma. This view has been challenged by Needl et al$^3$ who found evidence of bronchiectasis in 41% of lobes in a group of patients with allergic bronchopulmonary aspergillosis, and in 15% of lobes in asthmatic patients with a positive skin test for *A fumigatus* but without other features of allergic bronchopulmonary aspergillosis. Paganin et al$^4$ also found some degree of bronchiectasis on computed tomographic (CT) scanning in 56% of asthma patients with no evidence of *Aspergillus* allergy. Clearly, if this were the case it would have implications for the treatment and evaluation of therapies in chronic asthma.

Narrow section CT scanning is the investigation of choice in the diagnosis of bronchiectasis. It is superior to plain chest radiography in detecting bronchiectasis$^5$ and, in comparison with bronchography which is considered unsafe in asthma,$^7$ has a sensitivity in some series approaching 95% and a specificity of around 90%.$^8$ We have applied CT scanning to a group of patients with allergic bronchopulmonary aspergillosis and to a group of asthmatic patients with a positive skin test to *A fumigatus* but without other features of allergic bronchopulmonary aspergillosis. Our aim was to determine the extent of bronchiectatic changes in allergic bronchopulmonary aspergillosis and to establish whether or not a similar spectrum of destructive changes is common in the other asthmatic patients.

**Methods**

**PATIENTS**

Patients were identified from case records and were seen prospectively. All patients were asthmatic and demonstrated a positive skin prick test to *A fumigatus*. Allergic bronchopulmonary aspergillosis was diagnosed if, in addition, the patients had positive precipitins to *A
**Computed tomographic scanning of the lung**

*fumigatus* and had a history of a flare in their symptoms associated with a positive sputum culture for *A fumigatus*. Radiological features were not used in patient selection. Seventeen patients with allergic bronchopulmonary aspergillosis of mean (SE) age 60.1 (2.5) years, FEV\(_1\) 1.3 (0.14) litres and 49.4 (5.8) % predicted, and 11 asthmatic patients with a positive skin test to allergic bronchopulmonary aspergillosis but with no other features of the disease of mean age 49.5 (4.5) years, FEV\(_1\) 2.1 (0.3) litres and 75.5 (6.5) % predicted were studied. Patient characteristics are detailed in table 1.

**CT scanning**

A Philips Tomoscan 310 with a 9.5 second scan time was used. Thin section studies were performed using a 3 mm slice thickness scanning at 9 mm increments and the images were reconstructed using a high spatial frequency algorithm. The CT images were analysed separately by two senior radiologists in a blinded fashion, differences being resolved by consensus.

Bronchiectasis was deemed to be present if the bronchial diameter was greater than that of the accompanying artery\(^9\)\(^10\) and was defined as being central when confined to the medial two thirds of the lung. The degree of bronchiectasis was also assessed, being allocated to one of three categories: mild — where the bronchial diameter was only slightly larger than the accompanying artery; marked — where the dilatation was obvious; and cystic — where the bronchi showed cystic dilatation.

Bronchial wall thickening was evaluated by comparison with areas of normal lung in any individual\(^9\)\(^10\) Other features including pleural thickening, parenchymal shadowing, volume loss, and emphysematous changes were also noted.

Each lobe in every patient was analysed separately.

**CHEST RADIOGRAPHS**

Posteroanterior chest radiographs were also performed at the time of scanning. These were reported separately from the CT scans, again in a blinded fashion and independently by the two radiologists. Bronchiectasis was diagnosed using the signs described by McCarthy et al.\(^11\) the following changes being accepted as bronchiectasis: parallel line shadows, band-like (tooth paste) shadows, gloved finger shadows, and ring shadows.

**DATA ANALYSIS**

Differences between groups were compared by the χ\(^2\) and continuous variables by the Mann-Whitney U test. The relation of IgE, IgG, and FEV\(_1\) with the grades of bronchiectasis was compared by analysis of variance. A p value of <0.05 was taken as being significant.

Analysis was performed on an Amstrad personal computer using the Minitab software package.

**Results**

Fourteen of the 17 patients with allergic bronchopulmonary aspergillosis had evidence of bronchiectasis on CT scanning compared with two of the 11 in the group without allergic bronchopulmonary aspergillosis (p<0.05). This difference was more significant when the number of lobes affected was considered. Evidence of bronchiectasis was found in 43 (42%) of a possible 102 lobes in the group with allergic bronchopulmonary aspergillosis compared with three (5%) of a possible 66 in the non-allergic bronchopulmonary aspergillosis group. When grades of bronchiectasis were compared they were found by inspection to be related to the specific IgE and IgG (p<0.05), but not to the FEV\(_1\). Bronchial dilatation was found to be central in most patients (figure, table 2); one patient had both central and peripheral changes. Of the 16 patients noted to have bronchiectasis on CT scanning, only 12 were detected on the chest radiograph (table 2).

---

**Table 1  Patient characteristics expressed as mean (SE) values**

<table>
<thead>
<tr>
<th></th>
<th>ABPA (n=17)</th>
<th>Non-ABPA (n=11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>M:F</td>
<td>12.5</td>
<td>5.6</td>
</tr>
<tr>
<td>Age (years)</td>
<td>60.1 (2.5)</td>
<td>49.5 (4.5)</td>
</tr>
<tr>
<td>Total IgE (mg/ml)</td>
<td>576 (169)</td>
<td>387 (226)</td>
</tr>
<tr>
<td>Asthma (years)</td>
<td>27.6 (5.3)</td>
<td>23.2 (5.4)</td>
</tr>
<tr>
<td>Diagnosis of ABPA (years)</td>
<td>7.5 (1.5)</td>
<td>7*</td>
</tr>
<tr>
<td>Inhaled corticosteroids</td>
<td>16</td>
<td>1*</td>
</tr>
<tr>
<td>Oral prednisolone</td>
<td>6</td>
<td>1</td>
</tr>
<tr>
<td>Current/ex-smoker</td>
<td>31</td>
<td>4</td>
</tr>
<tr>
<td>FEV(_1) (litres)</td>
<td>1.3 (0.14)</td>
<td>2.1 (0.3)*</td>
</tr>
<tr>
<td>FEV(_1) (% predicted)</td>
<td>49.4 (5.8)</td>
<td>75.5 (6.5)*</td>
</tr>
<tr>
<td>RAST IgE to <em>A fumigatus</em> (U/ml)</td>
<td>4.6 (4.2)</td>
<td>1.32 (1.0)</td>
</tr>
<tr>
<td>Specific IgG to <em>A fumigatus</em> (U/ml)</td>
<td>41.9 (16.7)</td>
<td>22 (1.6)*</td>
</tr>
<tr>
<td>ECP (µg/l)</td>
<td>17 (2.5)</td>
<td>15.5 (5.3)</td>
</tr>
</tbody>
</table>

*ABPA = allergic bronchopulmonary aspergillosis; ECP = eosinophil cationic protein.
*p<0.05.*
Bronchiectasis was a common feature of the group with allergic bronchopulmonary aspergillosis, affecting most patients and a large percentage of lobes. As with previous descriptions in allergic bronchopulmonary aspergillosis, the bronchiectasis noted was mainly situated centrally. In contrast, bronchiectasis was uncommon in patients without allergic bronchopulmonary aspergillosis. Signs of bronchiectasis were noted in only 12 of the 16 affected patients on the plain chest radiographs performed at the same time as the CT scans, re-emphasising the greater sensitivity of CT scanning.

In the patients with allergic bronchopulmonary aspergillosis bronchial dilatation was found in similar numbers of patients and lobes as was reported in the studies by Neeld et al and Currie et al. In contrast, bronchiectasis was found in only 5% of lobes of patients without allergic bronchopulmonary aspergillosis, whereas Neeld reported this in 15% of lobes in a similarly defined group. There may be some differences between their patients and those of the present study as the three patients with bronchiectasis in their group of eight non-allergic bronchopulmonary aspergillosis patients were taking oral corticosteroids, suggesting that they had more severe asthma; neither of our two non-allergic bronchopulmonary aspergillosis patients with bronchiectasis were taking oral corticosteroids. Our findings are in even more marked contrast to the findings of Paganin et al who recently reported that there was evidence of bronchiectasis on CT scanning in 56% of asthmatic patients across a varying severity of disease. The patients in their study were different in that none were smokers and none had evidence of hypersensitivity to Aspergillus. Similarly, some of their patients were scanned when acutely unwell which may exaggerate the incidence of bronchiectasis if acute transient dilatation occurred which resolved with treatment. Nevertheless, our findings would not corroborate their frequent finding of bronchiectasis in asthmatic patients. We also think it is unlikely that technical differences would account for this disparity although different section thicknesses and increments were used; Neeld used 1 mm sections at 15 mm intervals and Paganin used 1.5 mm sections at 10 or 20 mm intervals, compared with 3 mm sections at 9 mm intervals used in our study. Likewise, although there is a degree of subjectivity in the interpretation of scans, it seems unlikely that this would account for the differences reported as the same criteria for bronchial dilatation were used.

Pleural thickening was common in the patients with allergic bronchopulmonary aspergillosis but infrequent in those without the disease. Pleuritic chest pain has been described in allergic bronchopulmonary aspergillosis although, to our knowledge, pleural thickening has not been reported. The finding of pleural thickening presumably reflects changes following episodic pleural inflammation; it should be noted, however, that this was relatively minor and unlikely to be of clinical significance. Bronchial wall thickening was common and widespread, as described and highlights the inflammatory nature of asthma. Emphysematous changes were more common in the patients with allergic bronchopulmonary aspergillosis which is in keeping with the more severe degree of airflow obstruction noted in this group.

We conclude from our findings that bronchiectasis is common in allergic bronchopulmonary aspergillosis but occurs only occasionally in asthmatic patients with a positive skin test to *A fumigatus*. We would contend, therefore, that the presence of bronchiectasis should continue to be regarded as a diagnostic feature suggestive of allergic bronchopulmonary aspergillosis and should not be accepted.
Computed tomographic scanning of the lung

simply as a common feature of asthma. In the evaluation of patients CT scanning is therefore useful if allergic bronchopulmonary aspergillosis is considered as a possible diagnosis.

This study was supported by a grant from the Chest, Heart and Stroke Association (Scotland).

Computed tomographic scanning of the lung in patients with allergic bronchopulmonary aspergillosis and in asthmatic patients with a positive skin test to Aspergillus fumigatus.

R M Angus, M L Davies, M D Cowan, C McSharry and N C Thomson

doi: 10.1136/thx.49.6.586

Updated information and services can be found at:
http://thorax.bmj.com/content/49/6/586

These include:
Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/